Merck and Co Inc (MRK): INCY/MRK’s PR on phase-3 failure of Epac...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	826
Posts	119450
Boards Moderated	15
Alias Born	09/05/2002

DewDiligence

Re: None

Friday, 04/06/2018 9:44:44 AM

Friday, April 06, 2018 9:44:44 AM

INCY/MRK’s PR on phase-3 failure of Epacadostat as addend to Keytruda in melanoma

https://finance.yahoo.com/news/incyte-merck-phase-3-study-113000088.html

Incyte Corporation and Merck…today announced that an external Data Monitoring Committee (eDMC) review of the pivotal Phase 3 ECHO-301/KEYNOTE-252 study results evaluating Incyte’s epacadostat in combination with Merck’s KEYTRUDA in patients with unresectable or metastatic melanoma determined that the study did not meet the primary endpoint of improving progression-free survival in the overall population compared to KEYTRUDA monotherapy. The study’s second primary endpoint of overall survival also is not expected to reach statistical significance. Based on these results, and at the recommendation of the eDMC, the study will be stopped.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”